Preclinical pharmacology studies of zingerone with special reference to potential therapeutic applications

doi:10.5411/wji.v16.i1.111511

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 1

This Article

(47)

(50)

(0)

(11)

(1)

(951)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Immunology

ISSN

2219-2824

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Immunol. Jan 8, 2026; 16(1): 111511
Published online Jan 8, 2026. doi: 10.5411/wji.v16.i1.111511

Full Size Figure Download Figure

Figure 9 Diagrammatic representation of the protective effects of zingerone against hyperglycaemia and cisplatin-induced nephrotoxicity. AGEs: Advanced glycation end products; NF-κB: Nuclear factor kappa B; TNF-α: Tumor necrosis factor alpha; COX-2: Cyclooxygenase-2; iNOS: Inducible nitric oxide synthase; IL: Interleukins; PKC: Protein kinase C; NADPH: Nicotinamide adenine dinucleotide phosphate; TGF-β: Transforming growth factor-beta.

Citation: Singh B, Singh H, Kaur S, Singh B. Preclinical pharmacology studies of zingerone with special reference to potential therapeutic applications. World J Immunol 2026; 16(1): 111511
URL: https://www.wjgnet.com/2219-2824/full/v16/i1/111511.htm
DOI: https://dx.doi.org/10.5411/wji.v16.i1.111511

Singh B, Singh H, Kaur S, Singh B. Preclinical pharmacology studies of zingerone with special reference to potential therapeutic applications. World J Immunol 2026; 16(1): 111511 [DOI: 10.5411/wji.v16.i1.111511]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.